MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facilit...
MaaT Pharma production unit within Skyepharma's Skyehub

MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies

MaaT Pharma and Skyepharma Complete Construction of
Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies

• Major milestone achieved with new state-of-the-art microbiome facility spanning over 1600 m², completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe.
• MaaT Pharma is Skyepharma’s Skyehub Bioproduction® first resident company.

MaaT Pharma, a French clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to improving survival outcomes for patients with cancer, and Skyepharma, a French independent CDMO, expert in providing innovative solutions for bioproduction as well as complex drugs development and manufacturing, announced the completion of their new state-of-the-art microbiome facility and the transfer of MaaT Pharma’s production and development teams to the new site in Saint-Quentin-Fallavier. The companies had entered a partnership in February 2022 to build the largest cGMP facility, to date, for full ecosystem microbiome therapies in Europe. The new facility is spanning over 1600 m² facility. MaaT Pharma and Skyepharma are currently performing quality qualification according to GMP guidelines, with the first production campaign targeted to start  by the end of Q3 2023.

MaaT Pharma production unit within Skyepharma's Skyehub

MaaT Pharma production unit within Skyepharma’s Skyehub

With MaaT013, our lead asset currently in Phase 3, and MaaT033, our second drug candidate, nearing launch in a Phase 2b clinical study, we have reached a major milestone that will be fundamental to securing our market access strategy. This new GMP manufacturing facility is a testament to the continued growth of MaaT Pharma,” stated Hervé Affagard, CEO and co-founder of MaaT Pharma. “Thanks to our strategic partnership with Skyepharma, we have successfully completed the new infrastructure within a year. I also want to take the opportunity to thank the ABL Europe team who have hosted our GMP production since 2016.”
The on-time completion of our first Skyehub facility is a major achievement for Skyepharma and our partner MaaT Pharma. The whole team is proud to have demonstrated the appropriate  agility and expertise to deliver this state-of-the-art building and BioCDMO offering in the challenging 12-month timeframe,” added David Lescuyer, CEO and President of Skyepharma. This reliability is an uncompromising service we want to offer to the biotech partners that are joining us. This is an integral part of the outstanding value accelerator that the Skyehub is providing them. “ Skyepharma is a recognized expert CDMO, offering solutions and technologies to develop hard- to-make oral solids and addresses the complex challenges faced by its worldwide partners to improve patients’ lives. Backed by its strong and continuous double-digit growth over the past 7 years, Skyepharma has continuously invested to keep its offering ever more innovative and focused on customer experience, and ultimately the patients. With the Skyehub Bioproduction® model, Skyepharma can also propose a unique capacity and service offering in the demanding bioproduction area. The completion of this new infrastructure brings with it positive impacts for the regional and national economy. Overall, the partnership between MaaT Pharma and Skyepharma could lead to the creation of a dozen jobs for specialized workers in the industry over the coming years. These therapies demand advanced manufacturing techniques and procedures and will contribute to the growth of the microbiome sector in France.